DelveInsight’s, “Metastatic Breast Cancer Pipeline Insight, 2022,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Metastatic Breast Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key takeaways from Metastatic Breast Cancer Pipeline Report
- DelveInsight’s Metastatic Breast Cancer Pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Metastatic Breast Cancer treatment.
- The leading Metastatic Breast Cancer Companies includes RemeGen, SynCore Biotechnology, Allarity Therapeutics, Daiichi Sankyo Company, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Byondis B.V., Jiangsu Hansoh Pharmaceutical Co., Ltd., Shanghai Miracogen Inc., Ambrx, Inc., Daehwa Pharmaceutical Co., Ltd., Phoenix Molecular Designs, Menarini Group, Samus Therapeutics, Inc., Hanmi Pharmaceutical Company Limited, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Immutep Limited, Arvinas Inc., G1 Therapeutics, Mirati Therapeutics Inc., Chia Tai Tianqing Pharmaceutical, Shanghai Pharmaceuticals Holding Co., Ltd, Pfizer, OncoTherapy Science, Inc., Eisai Inc., Dizal Pharmaceuticals, Tyme, Inc, Orion Pharma, HiberCell, Inc., Rhizen Pharmaceuticals SA, Hutchison Medipharma Limited, OncoPep Inc., Taizhou Hanzhong biomedical co. LTD, Kind Pharmaceuticals LLC, Dantari, Inc., Veru Inc., Taiho Oncology, Eli Lilly and Company, Sermonix Pharmaceuticals, Merus N.V., Minerva Biotechnologies Corporation, Kintara Therapeutics, Inc., Sichuan Baili Pharmaceutical Co., Ltd., Regor Pharmaceuticals Inc., Tianjin Hemay Biotech, Jiangsu Simcere Pharmaceutical Co., Ltd., and others are developing novel drug candidates to improve the Metastatic Breast Cancer treatment landscape.
- The promising Metastatic Breast Cancer pipeline therapies in various stages of development include Disitamab Vedotin, EndoTAG®-1 (SB05), Stenoparib (2X-121), U3-1402, KN026, trastuzumab duocarmazine, HS-10342, MRG002, ARX788, DHP107, PMD-026, PVX-410, HX008, Tenalisib, MEN1611, SM-88, HMPL-013, ODM-209, HC-5404-FU, RP12146, PU-H71, NOV120101, SC10914, Eftilagimod Alpha, ARV-471, E7090, DZD1516, G1T38, Sitravatinib, TQ-B211, B003, PF-06873600, OTS167PO, AND019, DAN-222, Enobosarm, Futibatinib, LY3484356, Lasofoxifene, MCLA-128, huMNC2-CAR44 CAR T cells, REM-001, GNC-035, RGT-419B, Hemay022, SCR-6852, and others.
- The companies and academics are working to assess challenges and seek opportunities that could influence Metastatic Breast Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Metastatic Breast Cancer.
Get an overview of the Metastatic Breast Cancer Pipeline landscape @ Metastatic Breast Cancer Pipeline Outlook
Metastatic Breast Cancer Overview
Metastatic breast cancer (also called stage IV) is breast cancer that has spread to another part of the body, most commonly the liver, brain, bones, or lungs. The symptoms of metastatic breast cancer can vary greatly depending on the location of the cancer. This section covers the symptoms of breast cancer that has spread to the bone, lung, brain, and liver, and the tests used to diagnose metastatic breast cancer. The most common symptom of breast cancer that has spread to the bone is a sudden, noticeable new pain. Breast cancer can spread to any bone, but most often spreads to the ribs, spine, pelvis, or the long bones in the arms and legs. Treatment for metastatic breast cancer often is based on systemic therapies, which use drugs rather than surgery or radiation. Metastases treatments are designed to shrink tumors and slow their growth, help ease symptoms and improve quality of life. Treatment may change, such as when one therapy stops working, or the side effects become too uncomfortable. Rather than having only one treatment, most patients undergo several treatments combined to help fight the cancer.
Latest Breakthroughs and Developments in the Metastatic Breast Cancer Pipeline Report
- On May 04, 2022, Rhizen Pharmaceuticals AG announced the presentation of promising interim data from an ongoing Ph2 trial of Tenalisib in locally advanced or metastatic breast cancer patients, at the ESMO Breast Cancer Meeting, in Berlin, Germany from May 3-5, 2022. Tenalisib was well tolerated and showed encouraging preliminary efficacy as a single agent in both primary and secondary resistant mBC; Data supports further development of Tenalisib in patients with HR+ and HER2- MBC.
- In April 2022, Alphamab Oncology announced that data from the phase II clinical study of the chemo-free regimen of KN026 in combination with KN046 (KN026-203) were presented as an E-poster at the AACR Annual Meeting 2022 (AACR 2022). As of August 10, 2021, 24 patients with HER2-positive other solid tumors (non-breast cancer/gastric cancer ) who received ≥1L prior systemic therapy were enrolled, 20 patients were evaluable for overall response: the ORR was 55.0%, the DCR was 85.0%, the 6-month PFS rate was 84.1%; Out of 11 evaluable CRC patients, the ORR and DCR was 45.5% and 90.9% respectively.
- In April 2022, Quantum Leap Healthcare Collaborative™ (Quantum Leap) and Ambrx Biopharma Inc., announced the selection of Ambrx’s antibody-drug conjugate (ADC) ARX788 for a new investigational treatment arm in the I-SPY 2.2 TRIAL for the treatment of HER2-positive breast cancer in the neoadjuvant setting. Sponsored by Quantum Leap, the I-SPY 2.2 TRIAL is a continuation of the I-SPY 2 TRIAL that seeks to create personalized treatments by adapting therapies for each patient to optimize the clinical outcome.
- In March 2022, TYME Technologies, Inc. announced the availability of the poster abstract, “SM-88, D/L-alpha-metyrosine, is a novel anti-cancer agent in estrogen receptor-positive breast cancer,” which was submitted by researchers from Georgetown University. The abstract was presented at the American Association for Cancer Research (AACR) Annual Meeting 2022 in New Orleans, LA. In September 2021, TYME Technologies, Inc. announced that the first patient had been dosed in the Phase II OASIS trial in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2 negative (“HR+/HER2-“) breast cancer who previously received a CDK4/6 inhibitor regimen being conducted by Georgetown University (NCT04720664) at several MedStar Health hospitals. (MedStar Health is Georgetown’s academic clinical partner.)
- In February 2022, Phoenix Molecular Designs (PhoenixMD), announced the completion of patient enrollment and dosing of PMD-026 in their Phase 1b monotherapy clinical trial. The successful completion of patient enrollment in this Phase 1/1b trial is an important step forward for PhoenixMD as they advance PMD-026 into Phase 2 combination trials for triple-negative breast cancer (TNBC) and hormone-positive breast cancer.
- In December 2021, Arvinas, Inc. and Pfizer Inc. announced an update on Phase 1 dose-escalation data of ARV-471, a novel PROTAC® estrogen receptor (ER) degrader, which is being co-developed for the treatment of patients with locally advanced or metastatic ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer (ER+/HER2-).
- In August 2021, Seagen Inc. and RemeGen Co., Ltd. announced that the two companies had entered into an exclusive worldwide licensing agreement to develop and commercialize disitamab vedotin, a novel HER2-targeted ADC.
Metastatic Breast Cancer Emerging Drugs
- Giredestrant: Roche
- Disitamab Vedotin: RemeGen
- EndoTAG®-1 (SB05): SynCore Biotechnology
- Stenoparib (2X-121): Allarity Therapeutics
Get to know more information about Metastatic Breast Cancer treatment therapies @ Metastatic Breast Cancer Clinical Trials
Metastatic Breast Cancer Pipeline Therapeutics Analysis
There are approx. 100+ key companies which are developing the therapies for Metastatic Breast Cancer. The companies which have their Metastatic Breast Cancer drug candidates in the most advanced stage, i.e. phase III include, Roche.
DelveInsight’s Metastatic Breast Cancer Pipeline Report covers around 100+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Discover more about therapy set to grab substantial Metastatic Breast Cancer Pipeline landscape @ Metastatic Breast Cancer Market Drivers and Barriers
Scope of the Metastatic Breast Cancer Pipeline Report
- Coverage- Global
- Metastatic Breast Cancer Companies– RemeGen, SynCore Biotechnology, Allarity Therapeutics, Daiichi Sankyo Company, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Byondis B.V., Jiangsu Hansoh Pharmaceutical Co., Ltd., Shanghai Miracogen Inc., Ambrx, Inc., Daehwa Pharmaceutical Co., Ltd., Phoenix Molecular Designs, Menarini Group, Samus Therapeutics, Inc., Hanmi Pharmaceutical Company Limited, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Immutep Limited, Arvinas Inc., G1 Therapeutics, Mirati Therapeutics Inc., Chia Tai Tianqing Pharmaceutical, Shanghai Pharmaceuticals Holding Co., Ltd, Pfizer, OncoTherapy Science, Inc., Eisai Inc., Dizal Pharmaceuticals, Tyme, Inc, Orion Pharma, HiberCell, Inc., Rhizen Pharmaceuticals SA, Hutchison Medipharma Limited, OncoPep Inc., Taizhou Hanzhong biomedical co. LTD, Kind Pharmaceuticals LLC, Dantari, Inc., Veru Inc., Taiho Oncology, Eli Lilly and Company, Sermonix Pharmaceuticals, Merus N.V., Minerva Biotechnologies Corporation, Kintara Therapeutics, Inc., Sichuan Baili Pharmaceutical Co., Ltd., Regor Pharmaceuticals Inc., Tianjin Hemay Biotech, Jiangsu Simcere Pharmaceutical Co., Ltd., and others
- Metastatic Breast Cancer Therapies– Disitamab Vedotin, EndoTAG®-1 (SB05), Stenoparib (2X-121), U3-1402, KN026, trastuzumab duocarmazine, HS-10342, MRG002, ARX788, DHP107, PMD-026, PVX-410, HX008, Tenalisib, MEN1611, SM-88, HMPL-013, ODM-209, HC-5404-FU, RP12146, PU-H71, NOV120101, SC10914, Eftilagimod Alpha, ARV-471, E7090, DZD1516, G1T38, Sitravatinib, TQ-B211, B003, PF-06873600, OTS167PO, AND019, DAN-222, Enobosarm, Futibatinib, LY3484356, Lasofoxifene, MCLA-128, huMNC2-CAR44 CAR T cells, REM-001, GNC-035, RGT-419B, Hemay022, SCR-6852, and others
- Metastatic Breast Cancer Therapeutic Assessment by Product Type
- Metastatic Breast Cancer Therapeutic Assessment by Stage and Product Type
- Metastatic Breast Cancer Therapeutic Assessment by Route of Administration
- Metastatic Breast Cancer Therapeutic Assessment by Stage and Route of Administration
- Metastatic Breast Cancer Therapeutic Assessment by Molecule Type
- Metastatic Breast Cancer Therapeutic Assessment by Stage and Molecule Type
- Metastatic Breast Cancer companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- Metastatic Breast Cancer – Market Drivers and Barriers
Table of Content
- Introduction
- Executive Summary
- Metastatic Breast Cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Metastatic Breast Cancer – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Giredestrant: Roche
- Mid-Stage Products (Phase II)
- Stenoparib – Allarity Therapeutics
- Early Stage Products (Phase I/II)
- ARV-471: Arvinas
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Inactive Products
- Metastatic Breast Cancer Key Companies
- Metastatic Breast Cancer Key Products
- Metastatic Breast Cancer- Unmet Needs
- Metastatic Breast Cancer- Market Drivers and Barriers
- Metastatic Breast Cancer- Future Perspectives and Conclusion
- Metastatic Breast Cancer Analyst Views
- Metastatic Breast Cancer Key Companies
- Appendix
Got Queries? Reach out for more information on the Metastatic Breast Cancer Pipeline Report- Metastatic Breast Cancer Pipeline Therapeutic Assessment
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/